A longitudinal study across two major U.S. health databases found nucleoside reverse transcriptase inhibitors to be associated with reduced Alzheimer's disease incidence.
In a 72-week study of hepatitis B patients, researchers found liver stiffness declines were driven by improved inflammation, not actual fibrosis regression.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.